Michael H. Davidson, MD, FACC, FACP, FNLA

With the results of ODYSSEY Outcomes and the more attractive pricing for PCSK9 inhibitors, how do you now see the landscape for this therapy, especially in the context of the lipid medicine/atherosclerosis specialist and the preventive cardiologist?

Clinical Professor

Video

With the ODYSSEY Outcomes Trial’s favorable pharmacoeconomic analysis now established—and a reduction in all-cause mortality with alirocumab— where do you see the evidence-based opportunities for these agents in your practice setting?

Michael H. Davidson, MD, FACC, FACP, FNLA

Clinical Professor

Video

The PCSK9 trials have confirmed (a) the absence of a J-point curve for LDL-C lowering and (b) continuing CV risk reduction, even when lowering LDL-C from 100 mg/dL to 30 mg/dL. In light of this how should the lipid specialist deploy PCSK9 inhibitors?

The PCSK9 trials have confirmed (a) the absence of a J-point curve for LDL-C lowering and (b) continuing CV risk reduction, even when lowering LDL-C from 100 mg/dL to 30 mg/dL. In light of this, how should the lipid specialist deploy PCSK9 inhibitors?

Michael H. Davidson, MD, FACC, FACP, FNLA

Clinical Professor

Video

You have introduced the concept of progressive atherosclerotic burden to characterize the multiplicity of biologic, metabolic & clinical markers in a CV risk profile. How do you apply this “aggregated risk” to patient selection for PCSK9 inhibitors?

Michael H. Davidson, MD, FACC, FACP, FNLA

Clinical Professor

Video

From a lipid specialist’s perspective, do the results from the ODYSSEY Outcomes Trial suggest the need to be more focused on achieving absolute target levels of LDL-C or relative percentage reductions in LDL-C levels?

Michael H. Davidson, MD, FACC, FACP, FNLA

Clinical Professor